

Special Issue

Personalized Immunotherapy for Cancers

Message from the Guest Editors

Immunotherapy revolutionized and renewed hope in cancer care and management. However, unlike many other therapies, immunotherapy is not tailored to individual needs, as we are still learning how to expand the benefits of immunotherapy. A path to the personalization of immunotherapy is to find how the disease and host interact and how the therapy disrupts their interaction. Therefore, we aim to answer the following questions within the scope of our Special Issue: (1) what are the metabolic features that impact the success of the immunotherapy (e.g., obesity, underlying morbidities, and ...)? (2) What are the biomarkers that are linked to resistance? (3) Are cancer targets (genetic, epigenetic, and proteome) altered with the standard of care, and are we developing modalities that relate to the right target? (4) How can we model the disease simply and comprehensively (complex in vitro and appropriate preclinical models recapitulating patients)? Tapping into current knowledge bases to understand these questions may pave the way to personalized immunotherapy.

Guest Editors

Dr. Zohreh Amoozgar

Edwin L. Steele Laboratories, Department of Radiation Oncology, Massachusetts General Hospital Cancer Center, Massachusetts General Hospital and Harvard Medical School, Boston, MA, USA

Dr. Igor Lucas Gomes-Santos

Edwin L. Steele Laboratories, Department of Radiation Oncology, Massachusetts General Hospital and Harvard Medical School, Boston, MA, USA

Deadline for manuscript submissions

closed (1 October 2024)



Cancers

an Open Access Journal
by MDPI

Impact Factor 4.4
CiteScore 8.8
Indexed in PubMed



mdpi.com/si/187699

Cancers
Editorial Office
MDPI, Grosspeteranlage 5
4052 Basel, Switzerland
Tel: +41 61 683 77 34
cancers@mdpi.com

[mdpi.com/journal/
cancers](https://mdpi.com/journal/cancers)





Cancers

an Open Access Journal
by MDPI

Impact Factor 4.4
CiteScore 8.8
Indexed in PubMed



[mdpi.com/journal/
cancers](https://mdpi.com/journal/cancers)



About the Journal

Message from the Editor-in-Chief

Cancers (ISSN 2072-6694) is an international, online journal addressing both clinical and basic science issues related to cancer research. The journal will continue its open access format, which will certainly evolve to ensure that the journal takes full advantage of the rapidly changing world of information and knowledge dissemination. It publishes high-quality clinical, translational, and basic science research on cancer prevention, initiation, progression, and treatment, as well as other related topics, particularly to capture the most seminal studies in the rapidly growing area of immunology, immunotherapy, and tumor microenvironment.

Editor-in-Chief

Prof. Dr. Samuel C. Mok

Department of Gynecologic Oncology and Reproductive Medicine, The University of Texas MD Anderson Cancer Center, Houston, TX 77030, USA

Author Benefits

Open Access:

free for readers, with article processing charges (APC) paid by authors or their institutions.

High Visibility:

indexed within Scopus, SCIE (Web of Science), PubMed, PMC, Embase, CAPlus / SciFinder, and other databases.

Journal Rank:

JCR - Q2 (Oncology) / CiteScore - Q1 (Oncology)